TY - JOUR
T1 - Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria
T2 - a post-hoc analysis of a prospective multicenter observational study
AU - the JAAM FORECAST Group
AU - Wada, Takeshi
AU - Yamakawa, Kazuma
AU - Kabata, Daijiro
AU - Abe, Toshikazu
AU - Fujishima, Seitaro
AU - Kushimoto, Shigeki
AU - Mayumi, Toshihiko
AU - Ogura, Hiroshi
AU - Saitoh, Daizoh
AU - Shiraishi, Atsushi
AU - Otomo, Yasuhiro
AU - Gando, Satoshi
AU - Sasaki, Junichi
AU - Kotani, Joji
AU - Takeyama, Naoshi
AU - Tsuruta, Ryosuke
AU - Takuma, Kiyotsugu
AU - Yamashita, Norio
AU - Shiraishi, Shin ichiro
AU - Ikeda, Hiroto
AU - Shiino, Yasukazu
AU - Tarui, Takehiko
AU - Nakada, Takaaki
AU - Hifumi, Toru
AU - Okamoto, Kohji
AU - Sakamoto, Yuichiro
AU - Hagiwara, Akiyoshi
AU - Masuno, Tomohiko
AU - Ueyama, Masashi
AU - Fujimi, Satoshi
AU - Umemura, Yutaka
AU - Mizobata, Yasumitsu
AU - Yamada, Yasuo
AU - Sugiyama, Satoru
AU - Ishida, Hiroshi
AU - Narimatsu, Eichi
AU - Miyasho, Koji
AU - Kanai, Toshio
AU - Miyatake, Satoru
AU - Iiduka, Ryouji
AU - Imamura, Hiroshi
AU - Mizushima, Yasuaki
AU - Sato, Yoshitake
AU - Nemoto, Manabu
AU - Hanada, Hiroyuki
AU - Shichinohe, Yasuo
AU - Hirahara, Kenji
AU - Kon, Akihide
AU - Sugita, Manabu
AU - Naoe, Yasutaka
N1 - Funding Information:
None of the authors declare any conflicts of interests in connection with the submitted article. TW reported receiving research funding from Takeda Science Foundation and personal fees from Asahi Kasei Pharma America Inc. and Asahi Kasei Pharma Japan Inc. outside the submitted work. AS reported receiving personal fees from CSL Behring outside the submitted work. All other authors have no conflicts of interest to declare.
Funding Information:
This study was supported by the Japanese Association for Acute Medicine (JAAM, 2014-01).
Funding Information:
The JAAM FORECST Study Group thanks Shuta Fukuda for his special assistance in completing the study. We would also like to thank Editage (www.editage.com) for English language editing. Moreover, we wish to express our gratitude to the JAAM FORECAST Study group, Keio University School of Medicine (Junichi Sasaki), Kobe University Graduate School of Medicine (Joji Kotani), Aichi Medical University Hospital (Naoshi Takeyama), Yamaguchi University Hospital (Ryosuke Tsuruta), Kawasaki Municipal Hospital (Kiyotsugu Takuma), Kurume University (Norio Yamashita), Aizu Chuo Hospital (Shin-ichiro Shiraishi), Teikyo University School of Medicine (Hiroto Ikeda), Kawasaki Medical School (Yasukazu Shiino), Kyorin University School of Medicine (Takehiko Tarui), Chiba University Graduate School of Medicine (Takaaki Nakada), St. Luke’s International Hospital (Toru Hifumi), Kitakyushu City Yahata Hospital (Kohji Okamoto), Saga University Hospital (Yuichiro Sakamoto), Center Hospital of the National Center for Global Health and Medicine (Akiyoshi Hagiwara), Nippon Medical School (Tomohiko Masuno), Community Healthcare Organization, Chukyo Hospital (Masashi Ueyama), Osaka General Medical Center (Satoshi Fujimi, Yutaka Umemura), and the JAAM FORECAST Sepsis investigators, Osaka City University Hospital (Yasumitsu Mizobata), National Hospital Organization Sendai Medical Center (Yasuo Yamada), Saitama Medical University Saitama Medical Center (Satoru Sugiyama), Fukui Prefectural Hospital (Hiroshi Ishida), Sapporo Medical University (Eichi Narimatsu), Fukuyama City Hospital (Koji Miyasho), Hiratsuka City Hospital (Toshio Kanai), Saiseikai Utsunomiya Hospital (Satoru Miyatake), Japanese Red Cross Society Kyoto Daini Hospital (Ryouji Iiduka), Shinsyu University School of Medicine (Hiroshi Imamura), Rinku General Medical Center (Yasuaki Mizushima), Subaru Health Insurance Society Ota Memorial Hospital (Yoshitake Sato), Saitama Medical University International Medical Center (Manabu Nemoto), Aomori Prefectural Central Hospital (Hiroyuki Hanada), National Hospital Organization Hokkaido Medical Center (Yasuo Shichinohe), Saga-ken Medical Centre Koseikan (Kenji Hirahara), Hachinohe City Hospital (Akihide Kon), Juntendo University Nerima Hospital (Manabu Sugita), Kawaguchi Municipal Medical Center (Yasutaka Naoe), Kakogawa West City Hospital (Manabu Kirita), Osaka National Hospital (Daikai Sadamitsu), and Kouseiren Takaoka Hospital (Masahiro Yoshida).
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Background: The development of disseminated intravascular coagulation (DIC) in patients with sepsis has been repeatedly confirmed as a factor associated with poor prognosis. Anticoagulant therapy has been expected to improve sepsis patient outcomes, whereas no randomized controlled trials have demonstrated the survival benefit of anticoagulant therapies in non-specific overall sepsis. Patient selection based on the component of “high disease severity” in addition to “sepsis with DIC” has recently proved important in identifying appropriate targets for anticoagulant therapy. The aims of this study were to characterize “severe” sepsis DIC patients and to identify the patient population benefiting from anticoagulant therapy. Methods: This retrospective sub-analysis of a prospective multicenter study included 1,178 adult patients with severe sepsis from 59 intensive care units in Japan from January 2016 to March 2017. We examined the association of patient outcomes, including organ dysfunction and in-hospital mortality, with the DIC score and prothrombin time-international normalized ratio (PT-INR), one of the components of the DIC score, using multivariable regression models including the cross-product term between these indicators. Multivariate Cox proportional hazard regression analysis with non-linear restricted cubic spline including a three-way interaction term (anticoagulant therapy × the DIC score × PT-INR) was also performed. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination. Results: In total, we analyzed 1013 patients. The regression model showed that organ dysfunction and in-hospital mortality deteriorated with higher PT-INR values in the range of < 1.5 and that this trend was more pronounced with higher DIC scores. Three-way interaction analysis demonstrated that anticoagulant therapy was associated with better survival outcome in patients with a high DIC score and high PT-INR. Furthermore, we identified a DIC score ≥ 5 and PT-INR ≥ 1.5 as the clinical threshold for identification of optimal targets for anticoagulant therapy. Conclusions: The combined use of the DIC score and PT-INR helps in selecting the optimal patient population for anticoagulant therapy in sepsis-induced DIC. The results obtained from this study will provide valuable information regarding the study design of randomized controlled trials examining the effects of anticoagulant therapy for sepsis. Trial registration: UMIN-CTR, UMIN000019742. Registered on November 16, 2015.
AB - Background: The development of disseminated intravascular coagulation (DIC) in patients with sepsis has been repeatedly confirmed as a factor associated with poor prognosis. Anticoagulant therapy has been expected to improve sepsis patient outcomes, whereas no randomized controlled trials have demonstrated the survival benefit of anticoagulant therapies in non-specific overall sepsis. Patient selection based on the component of “high disease severity” in addition to “sepsis with DIC” has recently proved important in identifying appropriate targets for anticoagulant therapy. The aims of this study were to characterize “severe” sepsis DIC patients and to identify the patient population benefiting from anticoagulant therapy. Methods: This retrospective sub-analysis of a prospective multicenter study included 1,178 adult patients with severe sepsis from 59 intensive care units in Japan from January 2016 to March 2017. We examined the association of patient outcomes, including organ dysfunction and in-hospital mortality, with the DIC score and prothrombin time-international normalized ratio (PT-INR), one of the components of the DIC score, using multivariable regression models including the cross-product term between these indicators. Multivariate Cox proportional hazard regression analysis with non-linear restricted cubic spline including a three-way interaction term (anticoagulant therapy × the DIC score × PT-INR) was also performed. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination. Results: In total, we analyzed 1013 patients. The regression model showed that organ dysfunction and in-hospital mortality deteriorated with higher PT-INR values in the range of < 1.5 and that this trend was more pronounced with higher DIC scores. Three-way interaction analysis demonstrated that anticoagulant therapy was associated with better survival outcome in patients with a high DIC score and high PT-INR. Furthermore, we identified a DIC score ≥ 5 and PT-INR ≥ 1.5 as the clinical threshold for identification of optimal targets for anticoagulant therapy. Conclusions: The combined use of the DIC score and PT-INR helps in selecting the optimal patient population for anticoagulant therapy in sepsis-induced DIC. The results obtained from this study will provide valuable information regarding the study design of randomized controlled trials examining the effects of anticoagulant therapy for sepsis. Trial registration: UMIN-CTR, UMIN000019742. Registered on November 16, 2015.
KW - Anticoagulant therapy
KW - Disseminated intravascular coagulation
KW - Multiple organ dysfunction syndrome
KW - Prothrombin time
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=85150216409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150216409&partnerID=8YFLogxK
U2 - 10.1186/s40560-023-00656-5
DO - 10.1186/s40560-023-00656-5
M3 - Article
AN - SCOPUS:85150216409
SN - 2052-0492
VL - 11
JO - Journal of Intensive Care
JF - Journal of Intensive Care
IS - 1
M1 - 8
ER -